European pharmaceutical leaders, including Novartis CEO Vas Narasimhan and Sanofi’s Paul Hudson, have urged the EU to raise drug prices to align more closely with US levels to foster innovation. In a letter to the Financial Times, they argue that current lower prices in Europe hinder market growth and discourage investment, noting that 30% of new medicines in the US are not available in Europe within two years. They warn that without urgent action, European biopharma competitiveness will decline, especially amid increasing competition from China and looming tariff uncertainties.
Full Article
From trains to tanks: Germany’s rearmament marks industrial shift
For three generations, the Liebig family has built double-decker railcars in Görlitz, Germany, but the factory will soon produce components for military vehicles after defense contractor KNDS took over from Alstom, which shut down operations to cut costs. While KNDS plans to retain about 350 employees, Carsten Liebig, a retired train maker, laments the shift towards arms production amid Germany's deindustrialization, as the country experiences a surge in defense spending and a shift in skilled...
Read more